Preparation, characterization and in vitro study of bellidifolin nano-micelles. Issue 34 (10th August 2022)

• Record Type: Journal Article
• Authors: Gao, Fan; Chen, Ziyue; Zhou, Li; Xiao, Xuefeng; Wang, Lin; Liu, Xingchao; Wang, Chenggang; Guo, Qiuhong
• Is Part Of: RSC advances. Volume 12:Issue 34(2022)
• Page Start: 21982
• Page End: 21989
• Publication Date: 2022-08-10
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d2ra02779h
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : Bellidifolin (BEL), a xanthone compound, has significant therapeutic effectiveness in cardiac diseases such as arrhythmias. Abstract : Bellidifolin (BEL), a xanthone compound, has significant therapeutic effectiveness in cardiac diseases such as arrhythmias. However, BEL is limited in clinical applications by its hydrophobicity. In this work, we used BEL as the active pharmaceutical ingredient (API), and polyethylene glycol 15-hydroxy stearate (Kolliphor HS15) as the carrier to prepare BEL nano-micelles by a solvent-volatilization method. According to an analysis by differential scanning calorimetry (DSC), BEL was successfully encapsulated in HS15 as BEL nano-micelles with a 90% encapsulation rate, and particle size was 12.60 ± 0.074 nm in the shape of a sphere and electric potential was −4.76 ± 4.47 mV with good stability and sustained release characteristics. In addition, compared with free drugs, these nano-micelles can increase cellular uptake capacity, inhibit the proliferation of human cardiac fibroblasts, and down-regulate the expression of Smad-2, α-SMA, Collagen I, and Collagen III proteins in myocardial cells to improve myocardial fibrosis. In conclusion, the BEL nano-micelles can provide a new way for the theoretical basis for the clinical application of anti-cardiac fibrosis.